Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $7

Benzinga · 05/11/2023 05:21
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $7.5 to $7.